{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:13:12Z","timestamp":1790392392034,"version":"4.1.0"},"reference-count":65,"publisher":"BMJ","issue":"4","funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["130162\/2017-5"],"award-info":[{"award-number":["130162\/2017-5"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["303210\/2018-4"],"award-info":[{"award-number":["303210\/2018-4"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2019,10,28]]},"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Loss of function in either breast cancer type 1 susceptibility protein (BRCA1) or breast cancer type 2 susceptibility protein (BRCA2) is a major risk factor for epithelial ovarian cancer (EOC) development. BRCA1 or BRCA2 deficiencies are associated with short-term prognosis and might have importance for the treatment of women with the disease. However, the screening of all possible mechanisms of dysfunction is expensive, time-consuming and difficult to apply in clinical practice. On the other hand, immunohistochemistry (IHC) is a simple and reliable method to access the expression of several proteins in tumour tissues.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and methods<\/jats:title>\n                  <jats:p>This systematic review aims to evaluate the current usage of IHC to detect BRCA1 and BRCA2 deficiencies in EOC. We searched and evaluated all primary literature on the use of IHC for evaluating BRCA1 and BRCA2 proteins expression in EOC. The main concepts for the search were: ovarian neoplasms, IHC, BRCA1 and BRCA2.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Forty-four studies from 925 unique titles were included. A total of 4206 tumour samples were evaluated for BRCA1 and 1041 for BRCA2 expression. Twelve BRCA1 primary antibodies were used in 41 studies, and the most common was the MS110 clone (75.6%). Seven BRCA2 primary antibodies were used in ten studies. Using the cut-off of 10%, 47.0% of EOCs are associated with loss of BRCA1 and 34.5% with the loss of BRCA2 expression.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>IHC was effective to detect loss of BRCA1 protein expression in EOC; however, data on BRCA2 expression were heterogeneous and difficult to interpret.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jclinpath-2019-206276","type":"journal-article","created":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T17:15:46Z","timestamp":1573578946000},"page":"191-196","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":16,"title":["Immunohistochemistry for the detection of BRCA1 and BRCA2 proteins in patients with ovarian cancer: a systematic review"],"prefix":"10.1136","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1053-2046","authenticated-orcid":false,"given":"Lorena Alves","family":"Teixeira","sequence":"first","affiliation":[{"name":"Postgraduate Program in Gynecology and Obstetrics, Department of Gynecology and Obstetrics, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5758-5917","authenticated-orcid":false,"given":"Francisco Jose","family":"Candido dos Reis","sequence":"additional","affiliation":[{"name":"Postgraduate Program in Gynecology and Obstetrics, Department of Gynecology and Obstetrics, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,11,12]]},"reference":[{"key":"2025092508584237000_73.4.191.1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10166"},{"key":"2025092508584237000_73.4.191.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2015.11.011"},{"key":"2025092508584237000_73.4.191.3","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-013-3114-3"},{"key":"2025092508584237000_73.4.191.4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.humpath.2018.06.018","article-title":"Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics","volume":"80","author":"Prat","year":"2018","journal-title":"Hum Pathol"},{"key":"2025092508584237000_73.4.191.5","doi-asserted-by":"publisher","DOI":"10.1006\/excr.2000.5132"},{"key":"2025092508584237000_73.4.191.6","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0714"},{"key":"2025092508584237000_73.4.191.7","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2017-204787"},{"key":"2025092508584237000_73.4.191.8","doi-asserted-by":"crossref","unstructured":"Ellison G , Huang S , Carr H , et al . A reliable method for the detection of BRCA1 and BRCA2 mutations in fixed tumour tissue utilising multiplex PCR-based targeted next generation sequencing. BMC Clin Pathol 2015;15.doi:10.1186\/s12907-015-0004-6","DOI":"10.1186\/s12907-015-0004-6"},{"key":"2025092508584237000_73.4.191.9","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2016-103902"},{"key":"2025092508584237000_73.4.191.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2011.08.017"},{"key":"2025092508584237000_73.4.191.11","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e31826cabbd"},{"key":"2025092508584237000_73.4.191.12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu461"},{"key":"2025092508584237000_73.4.191.13","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.18632\/oncotarget.6569","article-title":"A chemotherapy response classifier based on support vector machines for high-grade serous ovarian carcinoma","volume":"7","author":"Sun","year":"2016","journal-title":"Oncotarget"},{"key":"2025092508584237000_73.4.191.14","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.54.6.476"},{"key":"2025092508584237000_73.4.191.15","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"2025092508584237000_73.4.191.16","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile APP for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"2025092508584237000_73.4.191.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"2025092508584237000_73.4.191.18","doi-asserted-by":"crossref","first-page":"62","DOI":"10.36330\/kmj.v17i1.1950","article-title":"Significant role of loss or reduced BRCA1 gene expression in clinical implication of ovarian cancer","volume":"17","author":"Al-Kashwan","year":"2017","journal-title":"Kufa Med J"},{"key":"2025092508584237000_73.4.191.19","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3892\/ol.2014.1878","article-title":"BRCA1 promoter hypermethylation in sporadic epithelial ovarian carcinoma: Association with low expression of BRCA1, improved survival and co-expression of DNA methyltransferases","volume":"7","author":"Bai","year":"2014","journal-title":"Oncol Lett"},{"key":"2025092508584237000_73.4.191.20","first-page":"5329","article-title":"Brca1 promoter region hypermethylation in ovarian carcinoma: a population-based study","volume":"60","author":"Baldwin","year":"2000","journal-title":"Cancer Res"},{"key":"2025092508584237000_73.4.191.21","doi-asserted-by":"crossref","unstructured":"Cho DH , Park HS , Park S-H , et al . The expression of DBC1\/CCAR2 is associated with poor prognosis of ovarian carcinoma. J Ovarian Res 2015;8.doi:10.1186\/s13048-015-0129-3","DOI":"10.1186\/s13048-015-0129-3"},{"key":"2025092508584237000_73.4.191.22","first-page":"112","article-title":"Expresi\u00f3n de BRCA1 en mujeres Con neoplasias epiteliales de ovario del Estado Carabobo, Venezuela","volume":"29","author":"Fern\u00e1ndez","year":"2017","journal-title":"Rev Venez Oncol"},{"key":"2025092508584237000_73.4.191.23","first-page":"653","article-title":"Evaluation of the BRCA1\/2 mutation as a prognostic marker in primary peritoneal serous cancer","volume":"03","author":"Furukawa","year":"2013","journal-title":"J Obstet Gynecol"},{"key":"2025092508584237000_73.4.191.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2013.01.015"},{"key":"2025092508584237000_73.4.191.25","first-page":"335","article-title":"Grading of the ovarian serous cystadencarcinomas, and its correlation with BRCA1 and p53 immunoreactivity","volume":"27","author":"Guenes","year":"2007","journal-title":"Turk Klin TIP Bilim Derg"},{"key":"2025092508584237000_73.4.191.26","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/PGP.0000000000000310","article-title":"The prognostic value of BRCA1 and PARP expression in epithelial ovarian carcinoma: immunohistochemical detection","volume":"36","author":"Hjortkj\u00e6r","year":"2017","journal-title":"Int J Gynecol Pathol"},{"key":"2025092508584237000_73.4.191.27","first-page":"1993","article-title":"Expression and clinical implication of Beclin1, HMGB1, p62, survivin, BRCA1 and ERCC1 in epithelial ovarian tumor tissues","volume":"20","author":"Ju","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2025092508584237000_73.4.191.28","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-00009577-200511000-00003"},{"key":"2025092508584237000_73.4.191.29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2000.tb00959.x"},{"key":"2025092508584237000_73.4.191.30","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.70"},{"key":"2025092508584237000_73.4.191.31","doi-asserted-by":"crossref","unstructured":"Li M , Li H , Liu F , et al . Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy. J Ovarian Res 2017;10.doi:10.1186\/s13048-017-0304-9","DOI":"10.1186\/s13048-017-0304-9"},{"key":"2025092508584237000_73.4.191.32","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2011.211"},{"key":"2025092508584237000_73.4.191.33","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2012.118"},{"key":"2025092508584237000_73.4.191.34","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3233\/CBM-150550","article-title":"Expression of potential biomarkers associated with homologous recombination repair in patients with ovarian or triple-negative breast cancer","volume":"16","author":"Nomura","year":"2016","journal-title":"CBM"},{"key":"2025092508584237000_73.4.191.35","first-page":"21","article-title":"Morphologically qnd immunohistochemically based screening criteria for selection of patients with possible mutation of BRCA1 gene in primary ovarian cancer","volume":"53","author":"Popovska","year":"2014","journal-title":"Akush Ginekol"},{"key":"2025092508584237000_73.4.191.36","doi-asserted-by":"crossref","first-page":"9479","DOI":"10.7314\/APJCP.2014.15.21.9479","article-title":"Methylation status and immunohistochemistry of BRCA1 in epithelial ovarian cancer","volume":"15","author":"Pradjatmo","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"2025092508584237000_73.4.191.37","doi-asserted-by":"crossref","unstructured":"Press JZ , De Luca A , Boyd N , et al . Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 2008;8.doi:10.1186\/1471-2407-8-17","DOI":"10.1186\/1471-2407-8-17"},{"key":"2025092508584237000_73.4.191.38","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e318227c990"},{"key":"2025092508584237000_73.4.191.39","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0215(20000801)87:3<317::AID-IJC2>3.0.CO;2-B"},{"key":"2025092508584237000_73.4.191.40","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.7314\/APJCP.2014.15.10.4275","article-title":"No association between BRCA1 immunohistochemical expression and tumor grade, stage or overall survival in platinum-treated epithelial ovarian cancer patients","volume":"15","author":"Shawky","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"2025092508584237000_73.4.191.41","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1007\/s13277-013-1558-5","article-title":"BRCA1 promoter hypermethylation and protein expression in ovarian carcinoma\u2014an Indian study","volume":"35","author":"Shilpa","year":"2014","journal-title":"Tumor Biol"},{"key":"2025092508584237000_73.4.191.42","first-page":"9","article-title":"Prevalence of BRCA1 expression in epithelial ovarian cancer: immunohistochemical study","volume":"90","author":"Sirisabya","year":"2007","journal-title":"J Med Assoc Thai"},{"key":"2025092508584237000_73.4.191.43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0412.2011.01121.x"},{"key":"2025092508584237000_73.4.191.44","doi-asserted-by":"crossref","first-page":"13587","DOI":"10.18632\/oncotarget.7277","article-title":"Association and prognostic significance of BRCA1\/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1\/PD-L1 in high grade serous ovarian cancer","volume":"7","author":"Strickland","year":"2016","journal-title":"Oncotarget"},{"key":"2025092508584237000_73.4.191.45","doi-asserted-by":"crossref","DOI":"10.1186\/1476-4598-8-48","article-title":"Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas","volume":"8","author":"Swisher","year":"2009","journal-title":"Mol Cancer"},{"key":"2025092508584237000_73.4.191.46","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1136\/ijgc-00009577-200602001-00026","article-title":"Brca1 expression in a large series of sporadic ovarian carcinomas: a gynecologic Oncology Group study","volume":"16 Suppl 1","author":"Thrall","year":"2006","journal-title":"Int J Gynecol Cancer"},{"key":"2025092508584237000_73.4.191.47","doi-asserted-by":"publisher","DOI":"10.1369\/jhc.7A7209.2007"},{"key":"2025092508584237000_73.4.191.48","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1179\/his.2009.32.4.202","article-title":"Immunohistochemical detection of BRCA-1 and BRCA-2 expression in human breast and ovarian tumors","volume":"32","author":"Vorrius","year":"2009","journal-title":"J Histotechnol"},{"key":"2025092508584237000_73.4.191.49","doi-asserted-by":"publisher","DOI":"10.1002\/path.1507"},{"key":"2025092508584237000_73.4.191.50","doi-asserted-by":"crossref","first-page":"6670","DOI":"10.18632\/oncotarget.3118","article-title":"Fibrillin-1, induced by Aurora-A but inhibited by BRCA2, promotes ovarian cancer metastasis","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget"},{"key":"2025092508584237000_73.4.191.51","first-page":"118","article-title":"[Clinicopathologic features observation of ovarian transitional cell tumors]","volume":"44","author":"Wang","year":"2015","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"key":"2025092508584237000_73.4.191.52","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq770"},{"key":"2025092508584237000_73.4.191.53","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-3171"},{"key":"2025092508584237000_73.4.191.54","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2011.44"},{"key":"2025092508584237000_73.4.191.55","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-014-9776-8"},{"key":"2025092508584237000_73.4.191.56","doi-asserted-by":"crossref","DOI":"10.1186\/s13048-015-0195-6","article-title":"Risk prediction model for epithelial ovarian cancer using molecular markers and clinical characteristics","volume":"8","author":"Zhang","year":"2015","journal-title":"J Ovarian Res"},{"key":"2025092508584237000_73.4.191.57","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1999.5664"},{"key":"2025092508584237000_73.4.191.58","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000001205"},{"key":"2025092508584237000_73.4.191.59","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2015.21"},{"key":"2025092508584237000_73.4.191.60","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw142"},{"key":"2025092508584237000_73.4.191.61","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/PAI.0000000000000311","article-title":"Immunohistochemical performance of estrogen and progesterone receptor antibodies on the Dako Omnis staining platform: evaluation in multicenter studies","volume":"25","author":"Hicks","year":"2017","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"2025092508584237000_73.4.191.62","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.6529"},{"key":"2025092508584237000_73.4.191.63","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810858"},{"key":"2025092508584237000_73.4.191.64","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.5512","article-title":"Comprehensive genomic profiling (CGP) with loss of heterozygosity (LOH) to identify therapeutically relevant subsets of ovarian cancer (OC)","volume":"35","author":"Elvin","year":"2017","journal-title":"JCO"},{"key":"2025092508584237000_73.4.191.65","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1327"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jclinpath-2019-206276","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T15:58:55Z","timestamp":1758815935000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jclinpath-2019-206276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,12]]},"references-count":65,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,3,20]]},"published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1136\/jclinpath-2019-206276"],"URL":"https:\/\/doi.org\/10.1136\/jclinpath-2019-206276","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,12]]}}}